Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin in Patients With Hypertrophic Cardiomyopathy
NCT05182658Phase 3Active, not recruiting
- Sponsor
- National Institute of Cardiology
- Start
- Jun 2022
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of empagliflozin in hypertrophic cardiomyopathy (HCM) (2 arms), sponsored by National Institute of Cardiology. Primary endpoints: Peak Oxygen Uptake at 12 months and Kansas City Cardiomyopathy Questionnaire Overall Summary Score at 12 months. Started Jun 2022; status: active, not recruiting.
02
Drugs
empagliflozin
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT05182658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05182658.